Leukocyte-nanomedicine system for targeted delivery and precise theragnostics

X. Li; Y. Lu; L.D. Kong; X.Y. Shi; A. Pich

doi:10.1016/j.chempr.2022.09.021

Leukocyte-nanomedicine system for targeted delivery and precise theragnostics

X. Li, Y. Lu, L.D. Kong, X.Y. Shi^*, A. Pich^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Targeted delivery of nanomedicines to disease sites via living cell carriers has attracted extensive attention, but a better way to direct nanomedicines to carriers is still under exploration. Recently in Nature Nanotechnology, Cruz et al. modified the binding peptides on nanomedicines to hitchhike with specifically activated leukocytes for improved therapy of venous thrombosis.

Original language	English
Pages (from-to)	2591-2593
Number of pages	3
Journal	Chem
Volume	8
Issue number	10
DOIs	https://doi.org/10.1016/j.chempr.2022.09.021
Publication status	Published - 13 Oct 2022

Keywords

INFLAMMATION

Access to Document

10.1016/j.chempr.2022.09.021Licence: Free access - publisher

Cite this

@article{5bb6c265d6d74546bd1ce61de298b2d9,

title = "Leukocyte-nanomedicine system for targeted delivery and precise theragnostics",

abstract = "Targeted delivery of nanomedicines to disease sites via living cell carriers has attracted extensive attention, but a better way to direct nanomedicines to carriers is still under exploration. Recently in Nature Nanotechnology, Cruz et al. modified the binding peptides on nanomedicines to hitchhike with specifically activated leukocytes for improved therapy of venous thrombosis.",

keywords = "INFLAMMATION",

author = "X. Li and Y. Lu and L.D. Kong and X.Y. Shi and A. Pich",

year = "2022",

month = oct,

day = "13",

doi = "10.1016/j.chempr.2022.09.021",

language = "English",

volume = "8",

pages = "2591--2593",

journal = "Chem",

issn = "2451-9294",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Leukocyte-nanomedicine system for targeted delivery and precise theragnostics

AU - Li, X.

AU - Lu, Y.

AU - Kong, L.D.

AU - Shi, X.Y.

AU - Pich, A.

PY - 2022/10/13

Y1 - 2022/10/13

N2 - Targeted delivery of nanomedicines to disease sites via living cell carriers has attracted extensive attention, but a better way to direct nanomedicines to carriers is still under exploration. Recently in Nature Nanotechnology, Cruz et al. modified the binding peptides on nanomedicines to hitchhike with specifically activated leukocytes for improved therapy of venous thrombosis.

AB - Targeted delivery of nanomedicines to disease sites via living cell carriers has attracted extensive attention, but a better way to direct nanomedicines to carriers is still under exploration. Recently in Nature Nanotechnology, Cruz et al. modified the binding peptides on nanomedicines to hitchhike with specifically activated leukocytes for improved therapy of venous thrombosis.

KW - INFLAMMATION

U2 - 10.1016/j.chempr.2022.09.021

DO - 10.1016/j.chempr.2022.09.021

M3 - Editorial

SN - 2451-9294

VL - 8

SP - 2591

EP - 2593

JO - Chem

JF - Chem

IS - 10

ER -